Tardive Dyskinesia: Treat Functional Impairment, Not the AIMS Score
Psychiatric Times
JUNE 13, 2025
VMAT2 inhibitors, approved in 2017, represent a significant advancement in the treatment of TD, offering evidence-based options for managing symptoms. She has been on an antipsychotic medication to treat her bipolar disorder for 10 years, resulting in stability of mood symptoms that were previously poorly controlled.
Let's personalize your content